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Abstract
The human MRE11/RAD50/NBS1 (MRN) complex plays a crucial role in sensing and repairing DNA DSB. MRE11
possesses dual 3′−5′ exonuclease and endonuclease activity and forms the core of the multifunctional MRN complex.
We previously identified a C-terminally truncated form of MRE11 (TR-MRE11) associated with post-translational MRE11
degradation. Here we identified SPRTN as the essential protease for the formation of TR-MRE11 and characterised the
role of this MRE11 form in its DNA damage response (DDR). Using tandem mass spectrometry and site-directed
mutagenesis, the SPRTN-dependent cleavage site for MRE11 was identified between 559 and 580 amino acids. Despite
the intact interaction of TR-MRE11 with its constitutive core complex proteins RAD50 and NBS1, both nuclease
activities of truncated MRE11 were dramatically reduced due to its deficient binding to DNA. Furthermore, lack of the
MRE11 C-terminal decreased HR repair efficiency, very likely due to abolished recruitment of TR-MRE11 to the sites of
DNA damage, which consequently led to increased cellular radiosensitivity. The presence of this DNA repair-defective
TR-MRE11 could explain our previous finding that the high MRE11 protein expression by immunohistochemistry
correlates with improved survival following radical radiotherapy in bladder cancer patients.
Introduction
MRE11 is a component of the conserved
MRE11–RAD50–NBS1 (MRN) complex, a key player in
the early stages of the DNA damage response (DDR).
MRN is responsible for the recognition, repair, and sig-
nalling of DNA double-strand breaks (DSB)1,2 and is
required for homologous recombination (HR), classical
non-homologous end-joining (C-NHEJ) and alternative
non-homologous end-joining (A-NHEJ) pathways in
detection and signalling of DSBs3. Its effects are mediated
via its 3′−5′ exonuclease and single-stranded (ss) and
DNA hairpin endonuclease activities4–7. Absence of any
of its components leads to embryonic lethality in mam-
mals4. The 3′−5′ exo- and endonuclease activities of
MRE11 have specialised roles in HR repair and in sup-
porting ataxia-telangiectasia-mutated and Rad3- related
(ATR) kinase activation8,9. Abrogation of MRE11 nucle-
ase activity causes a striking array of phenotypes, indis-
tinguishable from the absence of MRN, including early
embryonic lethality and marked genomic instability2,9.
Inherited MRE11 mutations cause symptoms very similar
to the disease ataxia telangiectasia10–12.
We previously identified a C-terminally truncated form
of MRE11 (TR-MRE11) which is generated post-
translationally13. Here we investigate the cleavage site of
TR-MRE11, its effects on DNA damage repair following
ionising radiation and the likely associated protease.
Having identified the putative cleavage site, we success-
fully established stable TR-MRE11 cell lines and produced
recombinant truncated protein. TR-MRE11 lacked
nuclease activity and DNA binding efficiency whilst still
interacting efficiently with RAD50 and NBS1, thus likely
maintaining an intact MRN complex structure lacking the
MRE11 C-terminus. Cells expressing TR-MRE11 had
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deficient DNA damage repair function. Finally, we iden-
tified that the metalloprotease SPRTN as the key protease
that induces TR-MRE11 accumulation.
Materials and methods
Cell culture
293T cells were obtained from ATCC, Manassas, VA, in
2011, and maintained in high glucose DMEM (Gibco-
Thermo Fisher Scientific, CA) supplemented with 10% FBS
(Thermo Fisher, Waltham, CA) without antibiotics. The cell
lines RT112 and VM-CUB1 were purchased from the Ger-
man Collection of Microorganisms and Cell Cultures
(DSMZ), Braunschweig, Germany, and maintained in RPMI
medium (MilliporeSigma, Burlington, MA) or DMEM
medium (Gibco, Thermo Fisher Scientific, Waltham, MA),
respectively supplemented with 10% FBS without antibiotics.
Cells were maintained at 37 °C and 5% CO2 in a humidified
incubator. 293T cells were confirmed to be mycoplasma-
negative by PCR in January 2019. RT112 wildtype, RT112-
MRE11 KD, and RT112-full length MRE11 were confirmed
to be mycoplasma negative by PCR in September 2018. VM-
CUB1 wildtype, VM-CUB1-MRE11 KD, and VM-CUB1-full
length MRE11 were confirmed by MycoAlert (Lonza, Basel,
Switzerland) in February 2020. Cell lines were used up to 30
passages from original stock, including the transfection and
selection procedures.
Protein digestion, LC-MS/MS and data analysis of MRE11
pull down
RT112 cells (2 × 107 cells per dish) were plated in five
15 cm dishes and harvested 2 days later. Total protein
concentration was determined by BCA assay (Thermo
Fisher Scientific, Waltham, MA). For immunoprecipita-
tions, 10mg lysate was precleared with protein A/G
dynabeads (Thermo Fisher Scientific, Waltham, MA) at
4 °C for 60min. Lysates were incubated overnight with
anti-MRE11 antibody (ab214) then added to protein A/G
beads (40 µl) at 4 °C for 2 h. Beads were washed six times
in PBS and binding proteins eluted by boiling for 10min at
95 °C in 40 µl Laemmli buffer before running on an 4–20%
SDS-PAGE gel. After instant blue staining, bands corre-
sponding to FL- or TR-MRE11 were excised from the gel,
cut into small pieces and subjected to an in-gel-digest
process14. In brief, gel bands were destained, incubated
with 10mM DTT and 50mM iodacetamide before incu-
bating them with 60 ng of trypsin or elastase overnight at
37 °C. Peptides were extracted and dried down.
Dried peptides were reconstituted in 98% LC-MS/MS
water, 2% acetonitrile and 0.1% TFA. Fifty to fifty-eight
percent of the tryptic or elastase peptides were analysed
over 1 h gradient from 2 to 35% acetonitrile in 5%
dimethyl sulfoxide, 0.1% formic acid (at 250 nl/min) using
a Dionex Ultimate 3000 UPLC connected to an Orbitrap
Fusion Lumos trihybrid operated in data-dependent
acquisition mode (both instruments from Thermo).
Data were acquired with the universal method as descri-
bed previously15. Briefly, full MS scans were acquired in
the Orbitrap at 120 k resolution over a m/z range
400–1500, AGC target of 4e5 and S-lens RF of 30. Frag-
ment ion spectra (MS/MS) were acquired in the Orbitrap
(15 K resolution) with a Quad isolation window of 1.2,
AGC target of 5e4 and a maximum injection time of
40ms, with HCD activation and 28% collision energy.
MASCOT (vs2.4, Matrix Science) was used for peptide
and protein identification. Data were searched against the
human SwissProt database (downloaded 2017_08 for TR
MRE11 and 2017_07 for FL MRE11). MASCOT results
were reported after applying an ion score cut off of 20 and
a 1% FDR above identity or homology threshold.
Protein purification
FL-MRE11 and TR-MRE11 constructs were cloned into
pNIC28-Bsa4 and SUMO2-LIC vectors respectively by
LIC cleavage. Proteins were expressed in E. coli BL21
(DE3)-R3-pRARE in Terrific Broth and were induced
using IPTG (0.1 mM) at 18 °C (OD point 2–3). Cells were
harvested by centrifugation. For purification, cell pellets
were thawed and resuspended in buffer A (50 mM HEPES
pH 7.5, 500mM NaCl, 5% glycerol, 10 mM imidazole,
0.5 mM Tris (2-carboxyethyl) phosphene (TCEP)). Cells
were lysed using sonication and cell debris pelleted by
centrifugation. Lysates were applied to a Ni-NTA IMAC
gravity flow column (Qiagen, Hilden, Germany), washed
with two column volumes of wash buffer (buffer A sup-
plemented with 45mM imidazole), and eluted with the
addition of 300 mM imidazole in buffer A. For FL-
MRE11, the elution fraction was immediately con-
centrated, and gel filtration applied using a HiLoad 16/60
Superdex 200 column (GE health care, Chicago, IL).
Fractions containing FL-MRE11 were harvested and
cleaved with the addition of 1:20 mass ratio of TEV
protease. For TR-MRE11, the purification tag was cleaved
with the addition of 1:20 mass ratio of SUMO protease
during overnight dialysis into buffer B (20 mM HEPES,
pH 7.5, 500mM NaCl, 5% glycerol, 0.5 mM TCEP).
SUMO was removed by IMAC column rebinding and
final protein purification was performed by size exclusion
chromatography using a HiLoad 16/60 Superdex 200
column in buffer B at 1 ml/min in buffer B. Protein
concentrations were determined by measurement at
280 nm (Nanodrop) using the calculated molecular mass
and extinction coefficients, and intact masses were con-
firmed by ESI-MS. Coomassie stained gels of all con-
structs used in this study are shown in Fig. S4.
ESI-MS mass spectrometry
Thirty microlitre protein samples at 0.02 mg/ml in 0.1%
formic acid were injected onto a 4.6 × 50mm Zorbax
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5-μm 300SB-C3 column (AG883995-909; Agilent, Santa
Clara, CA) and resolved by reversed-phase chromato-
graphy at 40 °C. The solvent system was 0.1% formic acid
in double distilled H2O (buffer A) and 0.1% formic acid in
methanol (buffer B), with 1 min at 5% buffer B and then a
linear gradient of 5–95% buffer B over 6 min at 0.5 ml/
min. Protein intact mass was determined using an MSD-
TOF electrospray ionization orthogonal time-of-flight
mass spectrometer (Agilent Technologies, Palo Alto,
CA) operated in positive ion mode.
Fluorescence polarization
For the DNA binding assay, oligonucleotides were
chemically synthesized and purified by HPLC (Eurofins
Scientific, Luxembourg). The oligonucleotide sequences
were: TP423 (labelled with FITC at 5′): 5′-CTG CAG
GGT TTT TGT TCC AGT CTG TAG CAC TGT GTA
AGA CAG GCC AGA TC-3′; and TP424: 5′-CAC AGT
GCT ACA GAC TGG AAC AAA AAC CCT GCA GTA
CTC TAC TCA TCT C-3′. TP423 (labelled with FITC at
5′). TP424 oligonucleotides were mixed at 50 µM and
heated to 96 °C in a heat block and were allowed to cool
down slowly over 2 h to generate the 3′ overhanging DNA
duplexes probes. The 3′ overhanging DNA duplexes
(10 nM) were subsequently incubated with either purified
FL-MRE11 or TR-MRE11 (10 nmol/L) proteins in the
binding buffer (10mM Tris at pH 8.0, 25 mM NaCl, 0.1%
Tween20, 2 mM DTT) and fluorescence polarization
measured immediately by a PHERAstar FSX (BMG Lab-
tech, Aylesbury, UK) plate reader with excitation at
485 nm and emission at 520 nm. The FP values were
plotted against the log of the protein concentrations, and
the apparent dissociation constants were calculated from
fitting the curves with a sigmoidal four-parameter logistic
binding model.
Nuclease assay
The substrate for the nuclease assay was prepared as
detailed above using TP423 (labelled with FITC at 5’) and
TP424. Reactions (20 µl) contained 100 nM DNA in
HEPES buffer (25mM HEPES at pH 7.5, 20 mM KCl,
0.2% Tween-20, 2 mM DTT, and 5mM MnCl2). After
incubation for 5 min at 37 °C, the indicated amounts of
FL-MRE11 and TR-MRE11 were added, and incubation
was continued for 2 h at 37 °C. Reaction products were
run for 2 hr at 200 V on a 14% polyacrylamide gel with
8M urea in 1× TBE. Gels were visualised at 488 nm using
ChemiDoc (BioRad, Hercules, CA).
Transfection
RT112-MRE11 KD cells and VM-CUB1-MRE11 KD
cells were generated using psilencer-2.1-U6 neo (#5764;
Thermo Fisher, Waltham, MA), as per the manufacturer’s
recommendations. The shMRE11 sequences were as
follows: shMRE11 forward; 5′-GAT CCG AAC CTG GTC
CCA GAG GAG TTC AAG AGA CTC CTC TGG GAC
CAG GTT CTT TTT TGG AAA-3′; and shMRE11
reverse; 5′-AGC TTT TCC AAA AAA GAA CCT GGT
CCC AGA GGA GTC TCT TGA ACT CCT CTG GGA
CCA GGT TCG-3′. After 3 days of transfection, 500 µg/
ml of G418 was added for selection with complete media
(RPMI or DMEM medium supplemented with 10% FBS
for RT112 and VM-CUB1, respectively).
A lentiviral system was used to rescue full length
MRE11 or truncated MRE11 expression. 293T cells were
transfected in 10 cm dishes seeded at 5 × 106 cells per
dish, and 9 µg of either pLenti-full length MRE11 or
pLenti-truncated MRE11, 4.5 µg of psPAX2 (#12260;
Addgene, Watertown, MA), and 4.5 µg of pMD2.G
(#12259; Addgene, Watertown, MA) were delivered to
each dish with Lipofectamine 3000 (Thermo Fisher Sci-
entific, Waltham, MA) in Opti-MEM (Thermo Fisher,
Waltham, MA), according to the manufacturer’s instruc-
tions. The generated lentiviral particles were collected
48 hr following transfection and filtered through a
0.45 µm syringe filter (SLHV033RS; Millipore, Burlington,
MA). RT112-MRE11 KD and VM-CUB1-MRE11 KD cells
were infected with the filtered lentiviral supernatant using
8 µg/ml of polybrene. After 3 days of infection, 5 µg/ml of
puromycin was added for selection with complete media.
Ionising radiation
RT112-wildtype, VM-CUB1-wildtype, and MRE11-
mutated stable cell lines were collected or fixed at var-
ious time point after various dose of Cs-137 ionising
radiation (dose rate: 1.2 Gy/min) using a GSR-D1 irra-
diator (Gamma Services, Surrey, UK).
Vectors and site-directed mutagenesis
MRE11 sequences were inserted into the vector pLenti-
puro-CMV (P100022; Vigene, Rockville, MD). A Quick-
Change II XL Site-Directed Mutagenesis Kit (#200521;
Agilent, Santa Clara, CA) and XL10-Gold ultracompetent
cells were used for all site-directed mutagenesis according
to the manufacturers’ instructions. Sanger DNA sequen-
cing (Source Bioscience, Nottingham, UK) was used to
confirm the mutated nucleotides and the deleted
sequences.
Homologous recombination repair assay
DSB repair efficiency was measured as described pre-
viously16. Stable MRE11 knockdown cells were generated
from U2OS-I-SceI-GFP using psilencer-2.1-U6 neo
(#5764; Thermo Fisher, Scientific, Waltham, MA), as per
manufacturer’s recommendations. The sequence of
shMRE11 is mentioned in the ‘Transfection’ section of the
‘Material and methods’. In brief, 2.5 × 105 cells were see-
ded onto 6-well plates and transfected with 2.5 μg of
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pcDNA3.3-FL-MRE11 or pcDNA3.3-TR-MRE11 using
lipofectamine 3000, respectively. Following 24 h of
transfection, the cells had 2.5 μg of I-SceI expressing
plasmid added. The cells were allowed to grow for 24 h,
followed by the measurement of GFP+ cells by flow
cytometry, performed on a on a BD FACS DIVA instru-
ment (BD Biosciences, Franklin Lakes, NJ). The data were
analysed by FlowJo V10. One-way ANOVA was used to
determine the statistical significance of the experiments.
Western blotting
Protein lysis buffer comprised 50 mmol/L HEPES,
100mmol/L NaCl, 10 mmol/L EDTA, 1% Triton X-100,
4 mmol/L Na pyrophosphate, 2 mmol/L sodium ortho-
vanadate, 10 nmol/L NaF, and 50mmol/L B-
glycerophosphate. Cells were lysed in lysis buffer con-
taining a cocktail of proteinase inhibitors (Roche, Man-
nheim, Germany). Protein quantification of the lysates
was performed using a BCA protein assay (Thermo
Fisher, Waltham, MA) and 30 µg of protein was resolved
on 4–20% polyacrylamide gels and transferred onto
nitrocellulose membranes. The resulting membranes were
incubated with blocking buffer (Li-cor Biosciences, Lin-
coln, NE) and primary antibodies. The antibodies used
were anti-MRE11 (ab214; abcam, Cambridge, UK), anti-
MRE11 C-terminal (ab227452; abcam, Cambridge, UK),
anti-MRE11 N-terminal (sc-135992; Santa Cruz, Dallas,
TX), anti-myc-tag (2276 S; CST, Danvers, MA), anti-
phospho-histone H2A.X (Ser139) (2577; CST, Danvers,
MA), anti-SPRTN (HPA025073; Atlas antibodies,
Bromma, Sweden), anti-cdc25A (3652; CST, Danvers,
MA), anti-pAKT (S473) (4060; CST, Danvers, MA), anti-
VCP(p97) (10736-1-AP; Proteintech, Rosemont, IL), and
mouse monoclonal anti-β-actin (ab6276; abcam, Cam-
bridge, UK). Fluorochrome-conjugated secondary anti-
bodies (925-68021, 926-32210; Li-cor Biosciences,
Lincoln, NE) were detected by infrared scanning densi-
tometry using the Li-cor Odyssey Infrared Detection
System (Li-cor Biosciences, Lincoln, NE).
Immunoprecipitation
Cell lysates were prepared in Pierce IP lysis buffer
(Thermo; 87788). Total protein concentration was
determined by BCA assay and 500 μg lysate was incubated
with anti-MRE11 (ab214; abcam, Cambridge, UK) at 4 °C
overnight on a tube rotator and then added to protein A/
G plus agarose (sc2003; Santa Cruz, Dallas, TX) for 1 h at
4 °C. The beads were washed five times in PBS-Tween
0.05% and binding proteins eluted by boiling (95 °C for
10min) in 40 μL Laemmli buffer before SDS-PAGE gel
running. Ten percent of the total lysate was retained as
the load fraction. The antibodies used were anti-MRE11
(ab30725; abcam, Cambridge, UK), anti-RAD50 (3427;
CST, Danvers, MA), anti-NBS1 (NB100-143; Novus
Biological, Centennial, CO), anti-myc-tag (2278, CST,
Danvers, MA). To isolate SPRTN-interacting proteins,
whole cell lysates were prepared in lysis buffer (50 mM
Tris-HCl pH7.4; 150 mM NaCl; 0.1% NP-40; 1 mM
EDTA, and 5% glycerol; protease and phosphatase inhi-
bitors) containing 500 U/ml of benzonase at 4 °C. Flag-tag
protein complexes were separated using the anti-flag M2
antibody (F1804; Merck, Whitehouse Station, NJ) and
washed five times in IP buffer containing 0.05% NP-40
and eluted in 3xFlag peptide (F4799; Merck) for
30 min at RT.
Clonogenic assay
Established stable cell lines were plated in 6-cm culture
dishes containing 4ml of fresh medium with appropriate
numbers in triplicate irradiated at 0–8 Gy on the day after
cell plating and then incubated for 2 weeks. Cells were
stained with crystal violet staining solution (0.5%) in 80 ml
distilled water, 20 ml methanol and 0.5 g crystal violet
powder (Merck, Whitehouse Station, NJ). Colonies con-
taining more than 50 cells were counted and the surviving
fraction was determined as the total number of colonies
formed divided by the total number of cells plated mul-
tiplied by the plating efficiency, as determined in
untreated cells.
Cell cycle and apoptosis analysis
For cell cycle analysis, cells were seeded in 10-cm cul-
ture dishes at a density of 3 × 106 cells/dish. After 24 h,
two different doses of radiation (1 Gy, 5 Gy) were applied
and cells were incubated for 16 h. Cells were rinsed with
PBS, harvested with 0.05% trypsin, and fixed in 70%
ethanol overnight. Cells were stained with 25 μg/ml pro-
pidium iodide (PI) in 3.3 μg/ml ribonuclease A and 0.25%
triton X-100, and analysed on a FACS flow cytometer (BD
FACSCalibur, BD Biosciences).
FITC Annexin V (cat no. 556547, BD Pharmingen, San
Diego, CA) was used to quantitatively determine the
percentage of cells undergoing apoptosis according to the
manufacturer’s instruction. Established stable cell lines
were plated in 10-cm culture dishes containing 10ml of
fresh medium in appropriate numbers, irradiated to 4 and
8 Gy the day after cell plating and then incubated for 48 h
before harvest.
Immunofluorescence
Established stable cell lines were plated onto 8-well
chamber slides (734-2050; NUNC, Roskilde, Denmark)
and fixed with 100% methanol for 5 min at −20 °C, at each
time point after IR. Cells were then washed for 5 min
three times in PBS. All subsequent steps were carried out
at room temperature. Samples were blocked for 30min in
blocking buffer (1% BSA, 22.52 mg/ml glycine in PBST
(PBS+ 0.1% Tween 20)). Rabbit anti-phospho-histone
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H2A.X (Ser139) (#2577; CST, Danvers, MA) and mouse
anti-MRE11 (ab214; abcam, Cambridge, UK) were diluted
1:800 and 1:500, respectively in PBST and incubated
overnight at 4 °C. Cells were washed with PBS, after which
secondary antibodies [AlexaFluor 568 (A11036) and
AlexaFluor 488 (A21202; Thermo Fisher Scientific, Wal-
tham, MA)] were diluted 1:2000 in PBST and applied for
1 h at room temperature. Cells were washed with PBS as
before and mounted using proLong diamond antifade
mountant with DAPI (P36962; Thermo Fisher Scientific,
Waltham, MA). Cells were visualised for γH2AX immu-
nostaining using confocal microscopy (Zeiss 710; Zeiss,
Oberkochen, Germany).
RNA interference and plasmid transfection
siRNA for SPRTN (5′-GUCAGGAAGUUCU
GGUUAA-3′)17 transfections were performed using
Lipofectamine RNAiMax reagent (Thermo Fisher Scien-
tific, Waltham, MA) according to the manufacturer’s
instructions. Depletion was assayed 72 h post-
transfection. For SPRTN overexpression, both
pcDNA3.1-flag-SPRTN WT and SPRTN E112A plasmids
were used for transfection and this was performed using
Lipofectamine 3000 reagent (Thermo Fisher Scientific,
Waltham, MA) according to the manufacturer’s instruc-
tions. Overexpressed SPRTN levels were assayed 16 h
post-transfection.
In vitro cleavage of MRE11
Recombinant SPRTN wt or E112A mutant were pur-
ified from E. coli as detailed in ref. 18. Commercial
MRE11A (NM_005590) human recombinant protein was
purchased from Origene (Rockville, MD). Cleavage reac-
tions were performed in a 25 µL volume containing
500 ng MRE11, 2 µg SPRTN, and a 100 bp dsDNA oli-
gonucleotides (30:1 molar ratio SPRTN:dsDNA) in clea-
vage buffer (25mM Tris, pH7.4; 150mM NaCl) at 37 °C
for overnight (>16 h). The reaction was stopped by the
addition of Laemmli buffer and boiling and used
immediately.
Quantification and statistical analysis
Counting of γH2AX foci was determined using Image J
software. For clonogenic assays, the surviving fraction was
calculated on the basis of the number of colonies on non-
irradiated plates. Data are presented as the log of the
surviving fraction with error bars representing the SEM.
Radiation survival curves were plotted in GraphPad Prism
8, using the linear-quadratic model with the equation SF
= exp – (αD+ βD2), where D is a dose of radiation. The
FP values were plotted against the log of the protein
concentrations, and the apparent dissociation constant
calculated from fitting the curves with a sigmoidal four-
parameter logistic binding model in GraphPad Prism 8.
Spearman’s correlation value was acquired through Ima-
geJ with colocalisation plugins, and P values for one-way
ANOVA multiple comparison was calculated in Graph-
Pad Prism 8. The levels and correlation between SPRTN
and TR-MRE11 were calculated using a 2-way ANOVA
multiple comparison and correlation, respectively, in
GraphPad Prism 8.
Results
MRE11 in primary bladder tumours shows a truncated
form which lacks the C-terminus
Having previously identified a C-terminally truncated
form of MRE11 (TR-MRE11) in the bladder cancer cell
line RT112, and in T24 bladder cancer cells following
HDAC inhibition by panobinostat treatment13, we
extended our cell line panel to include seven other blad-
der cancer cell lines (Fig. 1A). In cell-free extracts taken
from primary bladder tumours at transurethral tumour
resection, we also found the presence of the truncation in
tumour samples from bladder cancer patients, but this
was not associated with clinical stage (Ta, T1 and T2)
(Fig. 1B).
We used two different antibodies against MRE11, which
bind to the central (ab214, 182–582aa) or C-terminal
regions (ab30725; 650aa-C-term) of full length MRE11,
respectively, to further elucidate the truncated phenotype
(Fig. 1C). TR-MRE11 was not detected with the antibody
ab30725 which targets an epitope in the C-terminal
domain in either RT112 or VM-CUB1 cell lines. However,
both forms were detected by the antibody ab214, targeting
amino acids 182–582 in RT112 but not in VM-CUB1 cells
(Fig. 1D). This indicate that TR-MRE11 does not include
the C-terminal region of MRE11, and not all cell lines
express TR-MRE11 forms at baseline.
Previously, our group demonstrated the existence of
TR-MRE11 by mass spectrometric analysis13. To identify
the MRE11 truncation locus, we optimised the MRE11
pull down by increasing the initial amount of protein and
repeated the mass spectrometry experiment using two
different proteases (trypsin and elastase), in order to
maximise protein sequence coverage (Fig. 1E). There was
71% protein sequence coverage following trypsin diges-
tion and 71% coverage after elastase digest of the upper
band representing FL-MRE11 (Fig. 1E-ii, iii). In the lower
MW band, we detected peptides covering MRE11 without
the C-terminus (31% and 38% coverage between 1 and
538 aa, respectively), with no coverage of sequence
between 539 and 708 aa (Fig. 1E-iv, v). The confidence in
protein identification, as represented by sequence cover-
age and emPAI, is shown in Table S1. We hypothesised
that the putative cleavage site (PCS) of MRE11 would lie
in the region between amino acid 539 and amino acid 600
for the following reasons: (1) Assuming that the tryptic
digest was complete, the arginine located at amino acid
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594 would have been cleaved by trypsin to generate a
peptide of 8-20 amino acid chain length detectable by
Mass Spectrometry, if TR-MRE11were included that
region. We, therefore, concluded that the PCS is located
before MRE11 amino acid 594. (2) If TR-MRE11 were
longer than 600 aa, the molecular weight of TR-MRE11
would be bigger than 68.4 kDa. However, the approximate
size of TR-MRE11 on western blots was smaller than
Fig. 1 MRE11 is found in truncated form in bladder cancer cell lines and primary bladder tumours. A Two out of nine bladder cancer cell lines
show a truncated form of MRE11 (approximately 65 kDa). Calgem is gemcitabine-resistant cells created from Cal29 by exposure to increasing
gemcitabine doses49. B Eight out of nine nuclear cell-free extracts from human bladder tumours show a truncated form of MRE11 (approximately
65 kDa). Ta= papillary tumour, T1= tumour invading lamina propria, T2= tumour invading muscularis propria. C Schematic diagram of MRE11 and
the epitope regions of MRE11 of two antibodies, spanning amino from acids 182 to 582 (ab214) and 650 to C-terminus (ab30725), respectively. D In
RT112, ab214, spanning amino acids 182–582, detected both FL and TR MRE11, but not in VM-CUB1. In contrast, the C-terminus anti-MRE11 antibody
(ab30725) did not detect the truncated MRE11 both in RT112 and VM-CUB1. E-i The eluted sample from super-paramagnetic beads with recombinant
protein A-bound MRE11 was loaded onto a precast 4–20% polyacrylamide gel. E-ii, iii The sequence coverage of FL-MRE11 digested with trypsin (red)
and elastase (blue) was 71% coverage for both cases. E-iv, v Protein sequence coverage of TR-MRE11 digested with trypsin (red) and elastase (blue)
were 23% and 28% respectively. The green box at K568 indicates the last amino acid of TR-MRE11 model.
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67 kDa. In case the cleaving enzyme worked in a more
distal region, we extended the range of the PCS to amino
acid 600, rather than restricting it to amino acid 594.
The cleavage site of MRE11 is between amino acids 559
and 580
We established a stable MRE11 KD cell line using
shMRE11 and found a 5.6-fold decrease in MRE11
expression compared to WT (Fig. S1A–C).
We removed the region of the PCS, namely, amino acids
539–600 (Fig. 2A) from the MRE11 plasmid. MRE11-wt
and PCS deleted (MRE11 Δ539–600) plasmids were
independently transfected into RT112 MRE11 KD cells,
and transfection efficiency determined by western blot
against the C-terminal myc-tag (Fig. 2C, S2). The cleaved
C-terminal part of MRE11 was detected in FL-MRE11
expressing cells but was absent in cells lacking the PCS
(MRE11 Δ539–600 aa), implying that MRE11 cannot be
cleaved when amino acids 539–600 are absent (Fig. 2A).
In order to further specify the PCS, we designed a set of
plasmids expressing various forms of MRE11 mutants, to
establish stable cell lines, using a myc-tag on the C-
terminal region of MRE11 (Fig. 2B). Thirty-eight cell lines
from six different deletions between 539 and 600 aa were
generated and representative cell lines with similar myc-
tag expression were selected (Fig. S2). The six deletions
were: 539–550 aa, 549–560–aa, 559–570 aa, 569–580–aa,
579–590 aa and 589–600 aa. The presence of two small
fragments containing myc-tag (~20 kDa) suggested that
MRE11 has two cleavage sites very near each other. The
higher of the two bands (~20 kDa) was absent in the
Δ559–570 aa and Δ569–580 aa deletion mutants, imply-
ing that the cleavage site is located between amino acids
559 and 580 aa (Fig. 2D). Thus, we designated 1–568 aa as
TR-MRE11 because from this experiment the cleavage
site was determined to lie at 569 ± 11 aa and, furthermore,
a run of glycine-arginine repeats started from amino acid
569. We, therefore, removed amino acids 569–708 to
generate a close representation of the TR-MRE11 form in
the lenti-viral vector (Fig. 2E). Of note, the level of
intrinsic disorder is very high after 500 aa in MRE11,
according to the predicted secondary structure of MRE11
(Fig. S3), and this could be one of the reasons why FL-
MRE11 is not stable at a post-translational level, allowing
TR-MRE11 forms to appear.
TR-MRE11 forms the intact MRN complex but lacks
nuclease activity
Its dual 3′−5′ exo- and endonuclease activity is one of
the most important biochemical features of MRE1119. To
determine whether the C-terminal truncation of MRE11
affected the enzymatic activity of MRE11, purified FL-
MRE11 (MRE11 wild-type), and TR-MRE11 (1–568 aa
only) recombinant proteins (Fig. S4A, S4C) were
identified and analysed by ESI-MS (Fig. S4B, S4D). When
compared to FL-MRE11, the nuclease activity of TR-
MRE11 on partial duplex dsDNA was abolished, in a
range of concentrations between 10 and 1000 nM (1:10,
1:1, 10:1 molar ratio protein:dsDNA) (Fig. 3A, B). The
nuclease products appeared to migrate approximately 34
nucleotides, consistent with the junction of the double
stranded regions and what has been observed pre-
viously20. To determine whether defective DNA binding
was responsible for the lack of nuclease activity, we per-
formed a fluorescence polarization-based DNA binding
assay21 sing the same substrates as in the nuclease assay
(Fig. 3C). The apparent affinity of TR-MRE11 was 7-fold
lower than FL-MRE11 (242.15 nM and 34.56 nM,
respectively). These data demonstrate that the C-terminus
contributed significantly to the DNA binding capacity and
nuclease activity of MRE11.
The MRE11 dimer is the core scaffold, and the correct
function of the MRN complex could be provided by the
flexibility of its interaction with RAD50 and NBS1, which
optimises MRN’s allosteric organisation22–24. We inves-
tigated TR-MRE11’s interaction with RAD50 and NBS1
by immunoprecipitation. Despite missing C-terminal
motifs, TR-MRE11 efficiently interacted with RAD50,
while NBS1 expression show a mild decrease over time
(Fig. 3D, S6B). Altogether, these results suggest that TR-
MRE11 maintains an intact MRN complex but the
nuclease activity of TR-MRE11 is abolished due to defi-
cient DNA binding.
γH2AX foci co-localised with FL-MRE11 but not with TR-
MRE11 after IR
We studied TR-MRE11 functions in bladder cancer cell
lines of the two main molecular subtypes of muscle-
invasive bladder cancer (RT112 for luminal and VM-
CUB1 for basal). Monoclonal cell lines expressing FL or
TR-MRE11 were established in both MRE11 KD RT112
and MRE11 KD VM-CUB1 bladder cancer cells using
lentivirus (Fig. 4A, S5A-B).
While the MRN complex binds to DNA double-strand
breaks (DSB)25, γH2AX is necessary for the recruitment
of other factors to the sites of DNA damage26. MRE11
undergoes relocalisation in the nuclei during DNA repli-
cation in damaged cells and this relocalisation reflects the
association of the complex with DNA damage27. We
found that MRE11 colocalised with γH2AX at 24 h post-
IR in WT and FL-MRE11, but colocalization levels
between MRE11 and γH2AX foci were decreased in TR-
MRE11 (Fig. 4B, C, S5C, D) in both cell lines.
In terms of γH2AX foci formation, using immuno-
fluorescence microscopy, we investigated γH2AX and
MRE11 foci at a 30min timepoint after IR which is
believed to be the peak time for formation of γH2AX foci.
As the number of MRE11 foci was reduced by MRE11 KD
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and this could be rescued by either FL-or TR-MRE11 (Fig
S5F) from MRE11 KD, no significant change in the
number of γH2AX foci was detected between FL- and TR-
MRE11 cell lines at 30 min post-IR (Fig S5G, H). How-
ever, the smaller numbers of γH2AX foci per MRE11 foci
were observed in TR-MRE11 compared to FL-MRE11 in
RT112 cell line (52 and 67 γH2AX foci per 100 MRE11
foci, respectively), consistent with the result of VM-CUB1
cell line (51 and 59 γH2AX foci per 100 MRE11 foci,
respectively) after IR, which indicates that the presence of
the MRE11 truncation alters the cell’s ability to increase
the phosphorylation of H2AX in response to ionising
radiation (post-IR, 24 hr) (Figs. S5C, E, 4B, D). Altogether,
this suggests that TR-MRE11 is less able to colocalise with
γH2AX, but that the truncation of MRE11 does not
influence the number of γH2AX foci formed immediately
after IR.
TR-MRE11 cells have less efficient HR repair, and are more
radiosensitive, with higher G2/M arrest than FL-MRE11
cells
The pattern of protein expression of the MRN components
was consistent after IR, indicating that the overall protein
level of each component of the MRN complex was
unchanged following ionising radiation (Fig. 5A, S6A).
MRE11 KD and TR-MRE11 cells had lower levels of γH2AX
protein expression in both non-irradiated and irradiated
samples compared to WT and FL-MRE11 samples, con-
sistent with immunofluorescence results (Fig. 4D, S5D). The
effect of the various MRE11 variants on the cell cycle was
evaluated by flow cytometric analysis. We observed that
MRE11 KD cells induced increased G2/M cell cycle arrest
(4.64-fold) after radiation (5Gy, 16 h), while control cells
showed 3.65 times increase under the same conditions (p <
0.0001) (Fig. 4F). This result is also consistent with the recent
report28 indicating that MRE11 deficit induces increased G2/
M arrest. We additionally identified that TR-MRE11 rescued
cells showed more G2/M arrest (4.31-fold) than FL-MRE11
rescued cells (3.78-fold) after IR (p < 0.05) (Fig. 4E, F), sug-
gesting that TR-MRE11 might have inefficient HR causing
cell cycle arrest.
To determine the role of the MRE11 C-terminus in the
HR repair pathway, we used the DR-GFP reporter system
in U2OS cells. We found that the FL-MRE11 and TR-
MRE11 exhibited a significant increase in the restoration
of the GFP+ cells over MRE11 KD cells (Fig. 5B). How-
ever, TR-MRE11 has been shown to significantly reduced
HR repair efficiency when compared with the FL-MRE11,
indicating the importance of C-terminal MRE11 in HR
repair. Radiotherapy increase overall survival in the basal
rather than the luminal cancer subtype29. Consistent with
this, VM-CUB1 cells were more sensitive to radiation
than RT112 cells in clonogenic assays (Fig. 5C, S6C). In
both cell lines, the degree of radiation sensitivity in FL-
MRE11 was similar to that of wild-type, while the degree
of radiation sensitivity in TR-MRE11 was similar to that of
MRE11 KD which is more radiosensitive (Fig. 5C, D,
S6D). To further evaluate whether the MRE11 deficient
cells’ sensitivity to IR is inducing apoptosis, we performed
FACS analysis using FITC annexin V and PI (Fig. 5E, F).
After both low (4 Gy) and high (8 Gy) doses of radiation,
MRE11 KD showed significantly increased early apoptosis
cells. TR-MRE11 cells had more early apoptosis cells than
FL-MRE11 at the higher radiation dose, but not at the
lower dose and not when compared to UT. No significant
difference was observed in late apoptosis cells upon
knockdown of MRE11 at either dose, although unex-
pectedly there was a difference between UT and trans-
fected FL-and TR-MRE11 cells, both showing significantly
less late apoptosis with this effect being more pronounced
with the FL-MRE11. The differences in apoptosis do not
fully explain the results in the survival assay, where a
significant difference was observed between FL-and TR-
MRE11 cells even at lower doses. MRE11 does appear to
play some role in early apoptosis but this role is not
particularly dependent on the C-terminus.
Taken together, these results indicate that the C-ter-
minus, including the glycine-arginine-rich (GAR) domain,
is important for choosing the more efficient DNA damage
repair pathway, G2/M progression, and cell survival after
IR, but does not appear to play a significant role in
apoptosis.
Formation of TR-MRE11 is not caspase-dependent
Previously, we showed that MRE11 cleavage occurs as a
post-translational modification but that TR-MRE11 is not
(see figure on previous page)
Fig. 2 The putative cleavage site in MRE11 lies within a 22 amino acid region, namely amino acids 559–580. A A map of the lentiviral vector
including either intact MRE11 or MRE11 with the initial putative cleavage site (PCS) at amino acids 539–600 removed. The functional domains of
MRE11 are indicated50,51. B Schematic representation of MRE11 with the various mutants, including complete deletion of the region (MRE11 PCS
removed) and sequential deletions of 12 amino acids (MRE11 Δ539–550, Δ549–560, Δ559–570, Δ569–580, Δ579–590 and Δ589–600). C The MRE11
mutant lacking the initial putative cleavage site failed to generate truncated MRE11. D MRE11 mutants lacking either 559–570 or 569–580 aa did not
generate the approximately 20 kDa size short form of cleaved MRE11 in RT112 cells, as seen using anti-myc-tag and anti-MRE11 ab 30725 antibodies.
E pLenti-TR-MRE11 vector was designed by deleting 569–708 aa from FL-MRE11 (amino acids deleted shown in upper panel). Lower panel shows the
truncation in diagrammatic form.
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generated due to alternative splicing, because no alter-
native MRE11 transcripts were detected in amplified
cDNA from MRE1113. To determine how the levels of FL
or TR-MRE11 expression are regulated, we first verified
which cellular processes contribute to the cleavage of FL-
MRE11 to produce TR-MRE11. To investigate how TR-
MRE11 is produced, we exposed cells to various forms of
damage, including overgrowth, starvation, blockage of
protein synthesis, induction of hypoxia, blocking of DNA
synthesis, HDAC inhibition, ionising radiation, and AKT
inhibition, as it is known the MRE11-dependent pathway
can contribute to localisation of pAKT-S47330,31. Among
these challenges only overgrowth significantly (P < 0.05)
increased TR-MRE11 (Figs. S1, S7A). We found that TR-
MRE11 expression depends on cell density. There was a
2.3-fold increase in TR-MRE11 with higher cell numbers
Fig. 3 TR-MRE11 lacks nuclease and DNA binding activities. A Nuclease assays of FL-MRE11 (lane 1, 2, 3, 4) and TR-MRE11 (lane 5, 6, 7, 8) on 3′-
overhang DNA substrates (n= 3). The FL-MRE11 shows clear dose-dependent nuclease activity which is absent in TR-MRE11. B Quantification of
nuclease activity data in (A). Error bars represent SEM (P < 0.0001 (****), P < 0.05 (*)). C Measurement of fluorescence polarisation (n= 1). The apparent
dissociation constant for FL-MRE11 was 34.56 nM, whilst TR-MRE11 showed significantly reduced DNA binding (242.15 nM). D TR-MRE11 was still able
to efficiently interact with RAD50 and NBS1, and this has been shown through immunoprecipitated MRE11 from VM-CUB1 protein lysates.
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(Fig. S1A–C). TR-MRE11 also increased in a cell density-
dependent manner (Fig. S1D, E). In order to elucidate the
mechanism, we first focused on the seven aspartic acids
which might be a potential target for caspases. We tested
a range of concentrations of the pan-caspase inhibitor Z-
VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]-fluoromethylketone) in DMSO. MRE11 cleavage
was not affected by inhibition with a range of doses of Z-
VAD-FMK (Fig. S7B). We next tested individual caspase
inhibitors 1, 2, 3, 4, 5, 6, 8, 9, 10 and 13, and again could
not detect any significant alteration in TR-MRE11
expression levels (Fig. S7C). This suggests that caspases
do not appear to be the proteases responsible for
cleaving MRE11.
MRE11 is a substrate of the SPRTN protease
We then chose to study the DNA-dependent mamma-
lian metalloprotease, SPRTN, which is essential for DNA-
protein crosslink (DPC) repair and DNA replication in
vertebrate cells32. SPRTN is a DNA-dependent, but
amino-acid sequence non-specific, protease. Its known
substrates (e.g. histones) are cleaved in disordered protein
regions in the vicinity of arginine, lysine and serine resi-
dues18. Thus SPRTN was a promising candidate respon-
sible for the MRE11 cleavage, as the C-terminus of
MRE11 is predicted to be intrinsically highly disordered
(Fig. S3). Furthermore, the MRE11 GAR domain (Fig. 2A),
located between 566–594 aa33, contains nine positively-
charged arginines out of its 29 amino acids and is also
disordered. This region could therefore be a possible
candidate substrate for SPRTN.
To investigate whether post-translational MRE11 clea-
vage is mediated by SPRTN, endogenous SPRTN was
depleted using siRNA targeting the 3′UTR of SPRTN
transcripts. Knockdown of SPRTN resulted in a dose-
dependent reduction in TR-MRE11 compared with
scrambled siRNA-treated samples (Fig. 6A, B) although
SPRTN knockdown did not influence to the protein
expression level of RAD50 and NBS1, the MRE11’s
interacting partners (Fig. S8C). There was a significant
correlation between TR-MRE11 and SPRTN levels (Fig.
6C). Unexpectedly, SPRTN expression decreased upon
treatment with HDACi (Fig S8A), and no effect was
observed upon overgrowth (Fig S8B). We also observed
large decrease in NBS1 and RAD50 upon treatment with
panobinostat, suggesting that this affects levels of multiple
cellular proteins. We overexpressed SPRTN protein to
investigate whether this influenced survival following
ionising radiation. Interestingly, overexpressed SPRTN
increased sensitivity to radiation therapy, and this may be
explained by the effect of SPRTN on MRE11 (Figs. 6D–F).
Moreover, the increased IR sensitivity of SPRTN in
MRE11 KD cells indicates that possible additional targets
of SPRTN may be involved. Together, these results indi-
cate that SPRTN is a factor mediating cleavage of MRE11
and overexpressed SPRTN increases radiosensitivity.
SPRTN protease cleaves MRE11 in vitro
To further investigate the role of SPRTN protease in
MRE11 cleavage, we performed an in vitro cleavage assay
using recombinant proteins. Recombinant MRE11 protein
was cleaved upon incubation with purified SPRTN
recombinant protein and 100 bp dsDNA in vitro, but not
with enzymatically-dead SPRTN variant (SPRTN E112A)
(Fig. 6G). Incubation of MRE11 with SPRTN yielded a
main N-terminal cleavage product of approximately
~65 kDa (arrow indicated) and others <17 kDa (bracket
indicated), which were absent when SPRTN-E112A was
used instead. In addition, the C-terminal binding antibody
detected a small fragment (<17 kDa) specifically produced
by SPRTN activity, reminiscent of the two small bands
from the cell lysate at ~12 kDa (Fig. 2D). This demon-
strates that the cleavage product generated by SPRTN is
missing the C-terminal of MRE11, similar to the TR-
MRE11 form in some bladder cancer cells (Fig. 1A, B).
These results suggest that TR-MRE11 could be a SPRTN
cleavage product. To investigate whether overexpressed
SPRTN and MRE11 form a stable interaction, we per-
formed immunoprecipitation using flag-SPRTN trans-
fection. Intact SPRTN complex was pulled down with its
interacting partners, and this was shown via anti-p97,
one of the strongest interacting partners to SPRTN (Fig.
6H). We did not detect a direct interaction between
SPRTN and FL-MRE11. Although the presence of a
stable interaction is not necessary for the protease
cleavage which can happen in a transient manner, we did
(see figure on previous page)
Fig. 4 TR-MRE11 co-localises less frequently than FL-MRE11with γH2AX after IR in VM-CUB1 cells. AWestern blot of established cell lines from
VM-CUB1. Endogenous MRE11 was knocked down and replaced with either exogenous FL or TR-MRE11, and named MRE11 knockdown (KD), FL-
MRE11, and TR-MRE11 cells, respectively. B Immunofluorescence microscopy of MRE11 and γH2AX foci showing co-localisation and some failure of
co-localisation after IR (2 Gy, 24 hr post-IR). MRE11 foci were clearly knocked down in the shMRE11 sample and rescued in FL and TR. C TR-MRE11
colocalises with γH2AX less than FL-MRE11 does. Data are presented as means ± SEM (P < 0.001 (***), P < 0.01 (**)). D Correlation between MRE11 and
γH2AX foci numbers from (B). MRE11 deficient and TR-MRE11 cells showed non-significantly lower slopes for γH2AX foci compared to FL-MRE11 and
untreated cells. E Representative graphs for propidium iodide cell cycle. F Cell cycle distribution of RT112 UT, KD, FL-MRE11, and TR-MRE11 cells was
quantitatively analysed using flow cytometry (****<0.0001, **<0.01, *P < 0.05; one-way ANOVA, n= 3, mean+ SEM).
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Fig. 5 Cells expressing TR-MRE11 are more radiosensitive and deficiency in HR repair than those expressing FL-MRE11. A The protein
expression levels of the MRN complex subunits were unchanged after IR (2 Gy). MRE11 KD and TR-MRE11 showed less increased level of γH2AX compared to
WT after IR. B GFP based reporter assay showing the efficiency of HR repair pathway under FL-MRE11 or TR-MRE11 rescued condition as indicated. Graph
represents the quantifications from three independent experiments (*P< 0.05; one-way ANOVA, n= 3, mean+ SEM). C Clonogenic survival rates of TR-
MRE11 and KD cells were lower than for FL-MRE11 and untreated cells. The response to ionising irradiation is represented by the linear-quadratic model. KD
cells had significantly lower survival rate than UT cells (P< 0.05). TR-MRE11 cells had significantly lower survival rate than FL-MRE11 (P< 0.05) at 4 Gy. D The
representative image of (C). E Flow cytometric analysis results of various RT112 cells after 8 Gy IR (48 h). F A statistical plot of annexin V-FITC/PI staining for (E) is
shown for both early and late apoptosis after 4 and 8 Gy IR (48 h). The results are expressed as the means ± SD (****<0.0001, **<0.01, *P< 0.05).
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detect some low molecular weight bands with the
monoclonal anti-MRE11 targeting 182–582 aa epitope
(Fig. 6H), which may correspond to MRE11 cleavage
products that interact with SPRTN. Further studies
would be required in order to investigate this possibility
more thoroughly.
Fig. 6 (See legend on next page.)
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Discussion
MRE11 has been intensively studied because of its
importance in genome stability, DNA damage repair, and
its nuclease activity. However, the reason why high
MRE11 protein expression, by immunohistochemistry
using an antibody with an epitope spanning amino acids
182–582, is associated with better survival rate in bladder
cancer patients after radiotherapy34,35 has not yet been
explained. We hypothesised that the truncated form of
MRE11 may explain the negative correlation between the
level of MRE11 expression and radiotherapy outcome, in
terms of DNA repair.
Human MRE11 bears a glycine-arginine-rich (GAR)
motif that is conserved among multicellular eukaryotic
species36. They are essential for not only the regulation of
MRE11 DNA binding and nuclease activity, but also
MRE11 and RAD51 focus formation on a unique DSB
in vivo33. Posttranslational modifications of MRE11, such
as methylated arginine GAR motif and DSB processing, as
well as ATR/CHK1 checkpoint signalling, appears to
influence DNA damage repair and has been demonstrated
previously37. According to Dery et al. 2008, MRE11-
ΔGAR on dsDNA displayed only weak residual exonu-
clease activity compared to that of methylated MRE11-
WT. Additionally, we have shown in this current report
that MRE11 recombinant protein without methylation
would also have lack of nuclease activity after cleavage.
Mutations in MRE11 are responsible for the human
radiation sensitivity disorder Ataxia-telangiectasia-like
disorder (ATLD), which is characterised by defective
checkpoint responses and high levels of chromosomal
abnormalities20. The authors found that in ATLD 1/2
where MRE11 contained a stop codon instead of R633,
~50% residual nuclease activity remained. Both MRE11-
ΔGAR and ATLD 1/2 share a number of key features,
such as having weak nuclease activity through loss of part
of MRE11. Furthermore, this paper offers the evidence
that the post-translationally induced TR-MRE11 forms
(G569stop) lost its nuclease activity due to lack of DNA
binding affinity (Fig. 3) reminiscent of MRE11-ΔGAR and
ATLD1/2. Despite this, TR-MRE11 interacted efficiently
with RAD50 and NBS1 (Fig. 3D, S6B). As truncated
MRE11 physiologically interacts with its MRN partners
but is completely defective in nuclease activity, it is likely
that the complex containing TR-MRE11 may have
reduced DNA binding and nuclease activity, but this
remains to be tested. Overall, a C-terminally truncated
form of MRE11 is capable of maintaining the interactions
between the MRN complex units while limiting its
enzyme activity.
MRE11 participates in both NHEJ and HR DNA repair
pathways7,38. Elimination of resection mechanisms
(MRE11Δexo1Δsgs1Δ triple mutants) prevents HR and
causes lethality in budding yeast39. Thus, we investigated
whether FL-MRE11 and TR-MRE11 cells displayed
similar ratios of HR repair pathway usage. In the HR assay
used in this study, FL-MRE11 cells promoted efficient HR
repair pathway compared to TR-MRE11 cells (Fig. 5B).
Furthermore, Xu et al. showed that MRE11 knockdown
caused radiosensitivity in an adenocarcinoma cell line40,
which resembles our finding in this paper. C-terminally
truncated MRE11 also caused radiosensitivity as MRE11
knockdown did but showed a lower degree of slope (Fig.
5C, D, S6C, D). The cell proliferation test using the MTT
assay did not reveal any significant results after various
doses of IR (Fig. S6E), indicating that MRE11 deficiency
mediated cell survival and cell cycle progression but did
not show dramatically altered cell proliferation rates.
Phosphorylated H2AX at ser 139 has been found at the
sites of DSB in chromosomal DNA and γH2AX is a key
component of various signalling pathways related to DNA
DSB41,42. γH2AX focus formation is considered to be a
sensitive signal for DNA DSB and necessary for rapid
DDR signal amplification43,44. In addition, γH2AX directly
binds NBS1 which then allows the recruitment of other
DDR proteins, including the MRN complex at DNA DSB
sites, and these foci co-localise with DNA repair and
checkpoint proteins26,45,46. γH2AX recruits the MRE11
complex to damaged DNA over time26,46. The level of co-
localisation with TR-MRE11 and γH2AX foci were
(see figure on previous page)
Fig. 6 MRE11 is cleaved in cells and in vitro by the SPRTN metalloprotease and SPRTN overexpression increases radiosensitivity. A siRNA-
targeting SPRTN in RT112 cells regulates the levels of TR-MRE11. siRNA was used indicated concentrations 40, 60, 80 and 100 nM for 72 h, with
scrambled siRNA as a positive control. Pictures are representative from 3 replicates with similar results. B Quantification of TR-MRE11 and SPRTN
knockdown level from (A). C A significant correlation was found between TR-MRE11 and SPRTN protein expression levels (p= 0.011). D Clonogenic
survival rates of SPRTN overexpressed cells were lower after IR than for WT cells in RT112. The response to ionising irradiation is represented by the
linear-quadratic model. MRE11 KD+SPRTN cells had significantly lower survival rate than WT+SPRTN cells (P < 0.05). WT+SPRTN cells had significantly
lower survival rate than WT (P < 0.05). E SPRTN overexpression in WT and MRE11 KD cells was confirmed by Western blotting. F The representative
images of (D). G In vitro cleavage assay using recombinant proteins. TR-MRE11, indicated with arrow, was released only in the presence of active
SPRTN. A blot for anti-MRE11 (C-terminus) antibody shows nonspecific binding to SPRTN protein, marked with asterisk. Cdc25A was used as a positive
control for SPRTN activity (the size of the cleaved products is ~5 kDa smaller than the products in Fig. 2D, as this recombinant protein does not
include tag part in C-terminus). H Immunoprecipitation of 293T cell lysate using SPRTN-WT and SPRTN-E112A. p97, the strong interacting partner for
SPRTN, was used as a positive control for SPRTN interacting protein.
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significantly lower than that of FL-MRE11, indicating that
the C-terminus of MRE11 is important for recognition of
MRE11 recruitment by γH2AX (Fig. 4B, C, S5C, D).
Our findings also address another key question of what
results in accumulation of TR-MRE11. The only factor
that appeared to have an effect on TR-MRE11 levels was
overgrowth or high cell density, which is known to affect
multiple cellular processes (Fig. S7). Some possible cas-
pase cleavage motifs including 560 (DSDD*SISA) aa in the
PCS of MRE11 were identified by Cascleave47. However,
we found no correlation (Fig. S7B, C) but found that
SPRTN metalloprotease was involved. MRE11 cleavage
was dependent on SPRTN and the level of TR-MRE11
was dependent on SPRTN expression (Fig. 6). These data
indicates that SPRTN can induce MRE11 truncated forms
in the cell. Further experiments are necessary to deter-
mine which of the domains in SPRTN is crucial for
MRE11 cleavage, either through rescuing SPRTN-wt or
SPRTN-mutated in SPRTN KD cells. Furthermore, the
physiological importance of MRE11 cleavage in SPRTN-
mediated DPC degradation should also be explored. The
Cancer Genome Atlas (TCGA) data reveals that higher
SPRTN levels were associated with decreased patient
survival rates, and it was elevated in some of cancer types
(Fig S8E, G). Furthermore, SPRTN levels were not sig-
nificantly correlated with MRE11 levels and were inde-
pendent of cancer stage (Fig S8D, F).
Previously, we found that bladder cancer patients with high
MRE11 expression paradoxically have shown higher survival
rates after radiation therapy, despite MRE11 being involved
in repair of DNA DSB caused by ionising radiation34. This
finding was validated by Laurberg et al. in an independent
cohort. These findings might now be explained due to the
presence of the truncated form of MRE11.
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